Core Viewpoint - MIRXES-B, a Singapore-based microRNA technology company, has seen its stock price rise significantly since its IPO, reflecting strong market interest and potential growth opportunities in the molecular diagnostics sector [1] Company Summary - MIRXES-B's stock price reached a new high of 47.8 HKD, marking an 8.1% increase during trading, with a market capitalization of approximately 13.2 billion HKD [1] - Since its listing on May 23, the stock has appreciated by 105% from its initial offering price of 23.3 HKD [1] Industry Summary - The company has signed a memorandum of understanding with PT DIASTIKA BIOTEKINDO, a company listed on the Indonesian stock exchange, to collaborate on the registration and commercialization of molecular diagnostic tests and related instruments for early detection and diagnosis of cancers with high incidence and mortality rates in Indonesia [1] - The memorandum is set for a duration of 12 months, indicating a strategic move to expand into emerging markets with high growth potential [1]

Group 1 - The company MiRXES-B (02629) has signed a memorandum of understanding with PT DIASTIKA BIOTEKINDO for collaboration in molecular diagnostic testing and related instruments for early detection and diagnosis of high-incidence and high-mortality cancers in Indonesia [1] - The memorandum is valid for 12 months from the date of signing [1] - The collaboration allows the company to leverage PT DIASTIKA BIOTEKINDO's existing channels to enter the Indonesian market with blood-based microRNA or multi-omics testing devices for high-incidence cancers such as gastric and lung cancer [1] Group 2 - The partnership enables the company to benefit from local policies in Indonesia, such as tax incentives for localization rates of 40% [1] - The collaboration aims to achieve regulatory flexibility under the ASEAN-centered medical device framework [1] - Indonesia is positioned as a pilot region for the company to replicate its business model in Southeast Asia, the Middle East, North Africa, and other regions with similar cancer profiles and healthcare structures [1]